BAP1 by IHC

Alphabetical Test listing

BAP1 by IHC-12376 - Technical only, 12379 - Technical & interpretation

  
BAP1 by IHC
  
12376 - Technical only, 12379 - Technical & interpretation
  
LAB12376
LAB12379
  
Ubiquitin carboxyl-terminal hydrolase BAP1
  

All IHC stains will include a positive control tissue

  
Tissue
  

Submit formalin-fixed, paraffin embedded (FFPE) tissue block

  

FFPE tissue block

  

Tissue section mounted on a charged, unstained slide

  

Ambient (preferred)

  
  • Unlabeled/mislabeled
  • Insufficient tissue
  • Slides broken beyond repair
  
AHL - Immunohistochemistry
  
Mo - Fr
  
1 - 2 days
  

Immunohistochemical staining and microscopic examination

  

If requested, an interpretive report will be provided

  

Specifications

BAP1 is a tumor suppressor protein frequently lost in mesotheliomas and in other malignant neoplasms including melanomas and carcinomas. Renal cell carcinoma and intrahepatic cholangiocarcinoma show frequent nuclear loss of BAP1. Loss of BAP1 nuclear staining has also been reported in other carcinomas including lung non-small cell carcinomas and breast cancer.

Staining pattern

  • Loss of nuclear BAP1 staining in a population of tumor cells defined by IHC as mesothelial in origin is diagnostic of malignant mesothelioma.
  • Intact nuclear staining is mesothelial cells does not rule out malignant mesothelioma. Consider additional testing (MTAP IHC, p16 FISH testing).

Loss of nuclear BAP1 staining in malignant mesothelioma. Nuclear BAP1 staining in background lymphocytes.

Applications

  • Loss of nuclear BAP1 staining can be used to differentiate mesothelioma from reactive mesothelial proliferations. Mesothelial origin should be first established using a a panel of IHC markers (WT-1, D240, Calretinin, MOC31, Claudin-4, etc.).
  • Loss of nuclear BAP1 staining by immunohistochemistry is highly concordant with BAP1 mutation, with a reported specificity of 100%.
  • Reported overall BAP1 sensitivity for pleural mesotheliomas is 50-65%. Reported sensitivity for mesothelioma subtypes: 61-77% for epithelioid mesothelioma, 33-49% for biphasic malignant mesothelioma, 0-22% for sarcomatoid mesothelioma. Reported sensitivity for peritoneal mesothelioma is estimated to be 55-67%  

References

  1. Hwang HC et al. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas. Am J Surg Pathol 2016;40(5):714-8.
  2. Hwang HC et al. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens. Am J Surg Pathol 2016;40:120–126.
  3. Cigognetti M et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Modern Pathology 2015;28:1043–1057.
  4. Andrici J et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Modern Pathology 2015; 28(10):1360-8.
  5. Chapel DB et al. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 2020;9 (Suppl 1): S3-S27.
  
88342 - 1st stain
88341 - each additional stain
  
02/22/2021
  
02/22/2021